J&J Gets Two Studies Closer To $5bn Sales Goal For Nipocalimab
Firm Reports Positive Data In Myasthenia Gravis And Sjögren’s
Analysts said full data from the VIVACITY study in generalized myasthenia gravis would be key to determining the drug’s competitive profile against approved anti-FcRn agents.
